Multidrug Resistance in Breast Cancer: Occurrence and Therapeutic Implications.
Annual rept. 1 Oct 94-30 Sep 95,
UNIVERSITY OF SOUTHERN CALIFORNIA LOS ANGELES
Pagination or Media Count:
We are continuing study of the therapeutic and biological implications of the overexpression of MDR1-Pglycoprotein in breast cancer. Two major thrusts have been initiated 1 organizing a clinical trial of paclitaxel without and with reversal of MDR1-Pglycoprotein action with the cyclosporin analog PSC-833 and 2 study of P-glycoprotein immunostaining in patients with primary and metastatic breast cancer available through our tumor bank. In addition, we are pursuing technical development to confirm these studies can be done from fixed section. The clinical trial that is to start will be a definitive test of the hypothesis that MDR1 is an important factor in determining response to paclitaxel in advanced breast cancer, and that a potent reversal agent will have therapeutic efficacy, at least in MDRl overexpressing tumors. In addition, pharmacodynamic information in relation to paclitaxel without or with PSC-833 will be forthcoming.
- Medicine and Medical Research